7-羟基异喹啉 | 7651-83-4

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 7-羟基异喹啉
• 英文名称: isoquinolin-7-ol
• 英文别名: 7-hydroxyisoquinoline
• CAS: 7651-83-4
• 化学式: C₉H₇NO
• mdl: MFCD00456131
• 分子量: 145.161
• InChiKey: WCRKBMABEPCYII-UHFFFAOYSA-N

物化性质

• 熔点：
  226-228°C
• 沸点：
  264.27°C (rough estimate)
• 密度：
  1.1555 (rough estimate)
• 溶解度：
  溶于甲醇和浓硫酸。
• 稳定性/保质期：

  如果按照规格正确使用和储存，则不会分解。避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密的容器中。应存放在阴凉、干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Hydroxyisoquinoline
Synonyms: Isoquinolin-7-ol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Hydroxyisoquinoline
CAS number: 7651-83-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H7NO
Molecular weight: 145.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-羟基异喹啉 在 platinum(IV) oxide 、 氢气 、 溶剂黄146 作用下， 生成 1,2,3,4-四氢异喹啉-7-醇
  参考文献：
  名称：

  发现新型基于噻吩并[2,3 - d ]嘧啶-4-基的Cyclin D1-CDK4抑制剂：合成，生物学评估和结构-活性关系。第2部分

  摘要：

  描述，设计和合成新型噻吩并[2,3 - d ]嘧啶-4-基类似物作为细胞周期蛋白依赖性激酶4（CDK4）抑制剂。重点研究the上带有取代苯基，4-[（（甲基氨基）甲基]苯甲醛（22）和5-异二氢吲哚甲醛（24）（6-叔丁基硫代[2,3- d ]嘧啶-已经鉴定出4-基）hydr衍生物。在本文中，讨论了我们合成化合物的效价，选择性和结构活性关系。

  DOI：

  10.1016/j.bmc.2009.10.039
• 作为产物：
  描述：

  7-甲氧基异喹啉 在 吡啶盐酸盐 作用下， 以 乙酸乙酯 为溶剂， 生成 7-羟基异喹啉
  参考文献：
  名称：

  Bicyclic compound and platelet aggregation inhibitor containing the same

  摘要：

  该发明涉及一种新型化合物，其化学式表示为（1），基于纤维蛋白原拮抗作用具有出色的抑制血小板聚集作用。含有化合物（1）的血小板聚集抑制剂作为有效成分对预防和治疗血栓形成以及经皮透支式冠状动脉成形术或经皮透支式冠状动脉再通术后的再狭窄或再闭塞具有有效性。

  公开号：

  US05629321A1

文献信息

• Total Synthesis of (±)-Cortistatin J from Furan
  作者：Mark G. Nilson、Raymond L. Funk

  DOI：10.1021/ja206138d

  日期：2011.8.17

  A concise, diastereoselective total synthesis of (±)-cortistatin J has been completed in 20 steps from furan. Key steps include an intramolecular [4 + 3] cyclization of a disubstituted furan with a (Z)-2-(trialkylsilyloxy)-2-enal to construct the tetracyclic core and a (Z)-vinylsilane/iminium ion cyclization to form the A ring.

  (±)-皮质抑素 J 的简洁、非对映选择性全合成已在 20 个步骤中从呋喃中完成。关键步骤包括双取代呋喃与 (Z)-2-(三烷基甲硅烷氧基)-2-烯醛的分子内 [4 + 3] 环化以构建四环核和 (Z)-乙烯基硅烷/亚胺离子环化以形成 A戒指。
• [EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE DÉMÉTHYLASE
  申请人：CHRYSALIS INC

  公开号：WO2017214413A1

  公开（公告）日：2017-12-14

  This disclosure relates, inter alia, to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

  这份披露涉及抑制组蛋白去甲基化酶活性的化合物等内容。具体而言，该披露涉及抑制组蛋白赖氨酸去甲基化酶KDM5B的化合物，药物组合物和使用方法，例如使用本文披露的化合物和药物组合物治疗癌症的方法。
• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。
• Synthesis of Indole-Dihydroisoquinoline Sulfonyl Ureas via Three-Component Reactions
  作者：Stuart Pearson、Shaun Fillery、Kristin Goldberg、Julie Demeritt、Jonathan Eden、Jonathan Finlayson、Anil Patel

  DOI：10.1055/s-0037-1610223

  日期：2018.12

  indoles in a 3-component reaction to generate a library of dihydroisoquinoline derivatives. Using a differential protecting group strategy, products could be further derivatised. Synthesis of isoquinoline starting materials using several different methods is also described. Isoquinolines activated with sulfamoyl chlorides were reacted with indoles in a 3-component reaction to generate a library of

  摘要 使氨磺酰氯活化的异喹啉在3组分反应中与吲哚反应，生成二氢异喹啉衍生物的文库。使用差异保护基团策略，可以进一步衍生产品。还描述了使用几种不同方法合成异喹啉原料。 使氨磺酰氯活化的异喹啉在3组分反应中与吲哚反应，生成二氢异喹啉衍生物的文库。使用差异保护基团策略，可以进一步衍生产品。还描述了使用几种不同方法合成异喹啉原料。

表征谱图